$140,959.87 ownership Payment -- Boehringer Ingelheim to Dr. Patricia Davis

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Boehringer Ingelheim made a $141.0K ownership payment to Patricia Davis, a Rheumatology specialist in Harrisburg, PA. This record details a significant ownership interest valued at $140,959.87. The payment was made by Boehringer Ingelheim, a major pharmaceutical company. Dr. Patricia Davis, a Rheumatologist in Harrisburg, PA, received this ownership interest.

Patient Guidance: What This Payment Means for You

This information relates to a financial ownership interest held by a physician, which may influence treatment decisions. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Ownership interests can be common in the pharmaceutical industry, but the substantial amount warrants attention within Rheumatology.

Regulatory Context: Sunshine Act Requirements

This disclosure is mandated under the Physician Payments Sunshine Act, part of the Affordable Care Act, to promote transparency.

Related Topics

This payment is related to the following healthcare transparency topics:

• ownership-interest
• pharmaceutical-company
• rheumatology
• physician-payment
• cms-open-payments
• boehringer-ingelheim

Understanding ownership Payments

Ownership and investment interest payments represent dividends, returns, or other financial benefits from physician ownership stakes in pharmaceutical or medical device companies. These relationships represent the most direct form of financial interest and are subject to the strictest reporting requirements under the Sunshine Act.

Frequently Asked Questions About This Payment

What was this $141.0K payment for?

This was a ownership payment of $141.0K from Boehringer Ingelheim to Patricia Davis, categorized as "Ownership or Investment Interest". The payment was reported under the Sunshine Act (CMS Open Payments).

Does Patricia Davis accept pharmaceutical money?

Yes, Patricia Davis received this $141.0K payment from Boehringer Ingelheim. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Patricia Davis's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this ownership payment?

A ownership payment of $141.0K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Rheumatology?

To compare this payment against Rheumatology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Rheumatology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Patricia Davis's relationship with Boehringer Ingelheim?

The payment type is 'ownership', indicating a financial stake rather than a service fee. This $141.0K ownership payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Rheumatology?

The date of payment is July 14, 2024, placing it within recent reporting periods.

What should patients do after learning about this payment?

This information relates to a financial ownership interest held by a physician, which may influence treatment decisions.

What else should I know about this ownership payment?

The payment ID 'OP-MNEUO6KR-83SQ26' allows for specific tracking of this transaction.

Related Reports

• View Dr. Patricia Davis's full payment report
• Boehringer Ingelheim full spending report
• Browse all Rheumatology payments
• Browse all payments in Pennsylvania
• Search for other payments